IDEXX Laboratories (IDXX) Q2 (USD): EPS 4.27 (exp. 3.94), Revenue 1.22bln (exp. 1.20bln), guides FY26 revenue between 4.7-4.75bln (exp. 4.71bln) and EPS between 14.69-14.94 (exp. 14.65)

IDEXX Laboratories (IDXX) Q2 (USD): EPS 4.27 (exp. 3.94), Revenue 1.22bln (exp. 1.20bln), guides FY26 revenue between 4.7-4.75bln (exp. 4.71bln) and EPS between 14.69-14.94 (exp. 14.65)

IDEXX has delivered a double beat on the quarter and lifted full-year guidance above the Street on both lines, a pattern the name has produced repeatedly through past reporting cycles given its recurring consumables-driven revenue base. The more consequential element is the guidance raise itself rather than the quarterly prints, since the market's reaction in this kind of name has historically hinged on whether management extends or merely reaffirms the path on companion animal diagnostics volumes and premium instrument placements. The distinction worth drawing is between organic growth in recurring consumables, which the Street treats as high quality, and one-off instrument or pricing effects, which tend to be discounted. Follow-ons are the call commentary on visit trends at veterinary practices, which have been the swing variable for the sector's volume assumptions, and any read-across to peers in animal health. FX exposure across Europe and Japan is a standard secondary line item for this issuer given its international mix.